AIM Concept Integration
3rd Year MBBS
Respiration
3rd Year MBBS
Respiration
Topic 8 — Bronchial Asthma and Its Pharmacotherapy
A rapid integration of airway pathology, clinical recognition, pharmacology, prevention and long-term control.
1. THE TOPIC IN ONE CONNECTED FLOW
Asthma connects airway inflammation with variable bronchoconstriction, mucus production and bronchial hyperresponsiveness. These changes explain the typical episodic symptoms, reversible airflow obstruction on spirometry and the need to combine bronchodilator therapy with anti-inflammatory control and trigger prevention.
Risk / Trigger
Atopy, allergens, infections, smoke, irritants or occupational exposure
Atopy, allergens, infections, smoke, irritants or occupational exposure
→
Airway Inflammation
Mast cells, T cells and eosinophils activate inflammatory pathways
Mast cells, T cells and eosinophils activate inflammatory pathways
→
Airway Change
Bronchoconstriction + mucosal edema + mucus + hyperresponsiveness
Bronchoconstriction + mucosal edema + mucus + hyperresponsiveness
→
Clinical Effect
Wheeze, cough, chest tightness and breathlessness
Wheeze, cough, chest tightness and breathlessness
→
Diagnostic Clue
Variable or reversible expiratory airflow limitation on spirometry
Variable or reversible expiratory airflow limitation on spirometry
→
Treatment
Bronchodilation + control of airway inflammation + trigger reduction
Bronchodilation + control of airway inflammation + trigger reduction
→
Outcome
Good control or, if severe, exacerbation, remodeling and respiratory failure
Good control or, if severe, exacerbation, remodeling and respiratory failure
2. KEY CLINICAL CONNECTIONS
Inflammation → Remodeling → Persistent Limitation
Recurrent inflammation
→
subepithelial fibrosis + smooth-muscle enlargement + goblet-cell hyperplasia
→
less completely reversible airflow limitation in long-standing disease.
→
subepithelial fibrosis + smooth-muscle enlargement + goblet-cell hyperplasia
→
less completely reversible airflow limitation in long-standing disease.
Symptoms → Spirometry → Diagnosis
Episodic wheeze or cough
→
obstructive expiratory pattern
→
improvement or variability in airflow supports asthma.
→
obstructive expiratory pattern
→
improvement or variability in airflow supports asthma.
Normal spirometry between attacks
→
does not exclude asthma because obstruction may be intermittent.
→
does not exclude asthma because obstruction may be intermittent.
Drug Target → Clinical Benefit
Beta-2 agonist
→
increased cyclic AMP
→
smooth-muscle relaxation and bronchodilation.
→
increased cyclic AMP
→
smooth-muscle relaxation and bronchodilation.
Corticosteroid
→
reduced inflammatory gene activity
→
better long-term control and fewer exacerbations.
→
reduced inflammatory gene activity
→
better long-term control and fewer exacerbations.
Exposure → Prevention / Referral
Tobacco smoke or workplace sensitizer
→
increased symptoms and exacerbation risk
→
exposure reduction improves control.
→
increased symptoms and exacerbation risk
→
exposure reduction improves control.
Persistent poor control or atypical features
→
reassessment and specialist referral when appropriate.
→
reassessment and specialist referral when appropriate.
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Airway inflammation → bronchial hyperresponsiveness → episodic bronchoconstriction, edema and mucus → variable airflow obstruction.
⭐ Type 2 inflammation → IgE and mast-cell activation + eosinophilic inflammation → allergic airway symptoms and persistent hyperresponsiveness.
Repeated inflammation → subepithelial fibrosis, smooth-muscle hypertrophy and mucus-gland enlargement → airway remodeling.
⭐ Variable symptoms + variable or reversible expiratory airflow limitation → strong diagnostic support for asthma.
Beta-2 agonists → increased cyclic AMP → rapid bronchodilation, while corticosteroids → suppression of airway inflammation → long-term disease control.
Antimuscarinics → reduced cholinergic bronchoconstriction; leukotriene antagonists → reduced mediator-driven bronchoconstriction and mucus; anti-IgE therapy → reduced allergic activation in selected patients.
⭐ Increasing exhaustion, altered consciousness or markedly reduced air entry → impending respiratory failure → urgent escalation of care.
Smoking, irritants or occupational exposure → poorer control and more exacerbations → prevention depends on trigger reduction, correct treatment, education and appropriate referral.
AIM Exam Trap: Less wheeze does not necessarily mean improvement. In severe asthma, critically reduced airflow may produce a “quiet chest,” indicating dangerous airway obstruction.